Other approaches for low to intermediate risk DLBCL comprise of alternative anthracycline-based combinations (R-ACVBP)[26], and for aggressive DLBCL dose-adjusted administration of cytotoxic agents (DA-EPOCH-R), which yields a durable remission in patients with MYC-rearranged B-cell lymphoma[27]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.